Cowen reissued their buy rating on shares of Urogen Pharma (NASDAQ:URGN) in a research report released on Tuesday morning.

Other research analysts also recently issued research reports about the company. ValuEngine upgraded Urogen Pharma from a hold rating to a buy rating in a research note on Saturday, June 2nd. Zacks Investment Research upgraded Urogen Pharma from a sell rating to a hold rating in a research note on Tuesday, May 15th. Finally, Oppenheimer set a $75.00 price target on Urogen Pharma and gave the stock a buy rating in a research note on Tuesday, May 15th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $57.00.

URGN opened at $42.53 on Tuesday. Urogen Pharma has a one year low of $17.10 and a one year high of $69.57. The stock has a market capitalization of $644.66 million, a PE ratio of -19.87 and a beta of 2.11.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, August 14th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.25). The firm had revenue of $0.36 million during the quarter. sell-side analysts forecast that Urogen Pharma will post -3.72 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Urogen Pharma during the 2nd quarter worth approximately $129,000. Quantbot Technologies LP purchased a new position in Urogen Pharma during the 1st quarter worth approximately $174,000. UBS Group AG grew its stake in Urogen Pharma by 31.5% during the 1st quarter. UBS Group AG now owns 3,611 shares of the company’s stock worth $180,000 after buying an additional 865 shares during the last quarter. DAFNA Capital Management LLC purchased a new position in Urogen Pharma during the 1st quarter worth approximately $224,000. Finally, Jane Street Group LLC purchased a new position in Urogen Pharma during the 2nd quarter worth approximately $227,000. Hedge funds and other institutional investors own 70.99% of the company’s stock.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. Its lead product candidates, MitoGel and VesiGel are proprietary formulations of the chemotherapy drug Mitomycin C, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Featured Story: Trading Penny Stocks

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.